Welcome to Our Parkinson's Place

I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please No advertisers, and No Information about Herbal treatments. Please no advertisements.
This is a free site for all.
Thank you.

Monday, July 10, 2017

Enzyme That May Trigger Alpha-Synuclein Aggregates and Parkinson’s Identified by Researchers


An enzyme called asparagine endopeptidase may participate in the development of Parkinson’s disease by cleaving alpha-synuclein protein into toxic fragments, according to new research.
The hallmark of Parkinson’s disease is the formation of alpha-synuclein clumps. But exactly how these clumps form in the brain has not been fully understood.
Now researchers have identified an enzyme called asparagine endopeptidase (AEP) that may contribute to the formation of alpha-synuclein aggregates.
“In Parkinson’s, alpha-synuclein behaves much like Tau in Alzheimer’s,” Keqiang Ye, PhD and senior author of the study, said in a news release. “We reasoned that if AEP cuts Tau, it’s very likely that it will cut alpha-synuclein, too.”
The team observed that AEP cleaves the human form of the sticky protein alpha-synuclein, causing it to form clumps and accumulate in neurons. This affects the normal functioning and survival of dopaminergic neurons (neurons that produce dopamine) and the release of dopamine.
Dopamine is an important neurotransmitter in the brain and controls brain regions involved in movement control. Lack of dopamine leads to movement deficits, one of the most common symptomsof Parkinson’s disease.
Researchers found that AEP is highly activated in the brains of patients with Parkinson’s disease. AEP cleaves, or cuts into alpha-synuclein, starting the cascade of events leading to the loss of dopaminergic neurons.
To confirm the toxic role of alpha-synuclein after being cut by AEP, researchers promoted the expression of the AEP-induced alpha-synuclein fragment in the substantia nigra (a brain region rich in dopaminergic neurons) in mice. This led to both dopaminergic neuronal loss and movement defects in these animals. But inhibiting or preventing this alpha-synuclein fragment decreased the toxic effects.
Together, these results support the role of AEP as a trigger of abnormal alpha-synuclein accumulation within neurons and as a key player in the pathology of Parkinson’s disease.
According to Ye, there are other enzymes besides AEP that cut alpha-synuclein into toxic pieces in neurons, and the intact form of the protein is also able to aggregate and trigger neuronal damage. However, he believes the results of this study may help others not only to better understand how alpha-synuclein clumps are formed, but also lead to the development of new treatments for Parkinson’s disease.

No comments:

Post a Comment